MarketBeat cites a USD 3.17 target for Inovio Pharmaceuticals stock
Published on 10/02/2026 at 21:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Inovio Pharmaceuticals (ISIN US45773H4092) has an average 12-month target of USD 3.17, according to MarketBeat on October 2, 2026. The average covers eight research firms, including five buy ratings, one strong buy, one hold and one sell.
FDA decision date stays October 30
The central value driver is INO-3107, Inovio's investigational DNA medicine for recurrent respiratory papillomatosis. The FDA review remains tied to an October 30, 2026 target action date, while the company has completed its late-cycle review meeting and scheduled pre-licensure inspections, according to the Q2 2026 earnings-call transcript published by Yahoo Finance.
The same transcript says Inovio completed a July 2026 equity offering that produced USD 18.3 million in net proceeds. Management said the financing extended the expected cash runway into late first quarter of 2027 and through a potential INO-3107 launch if approved.
Second-quarter loss narrows
Inovio reported a net loss of USD 6.0 million, or USD 0.07 per basic share, for the second quarter of 2026, compared with a USD 23.5 million loss, or USD 0.61 per share, in the second quarter of 2025, according to Yahoo Finance. The quarterly per-share loss also came in USD 0.15 better than the USD 0.22 consensus loss cited by MarketBeat.
Operating expenses fell to USD 18.6 million in the second quarter of 2026 from USD 23.1 million in the second quarter of 2025, a 19.48 percent reduction. Cash, cash equivalents and short-term investments stood at USD 36.7 million at the end of the second quarter, compared with USD 58.5 million on December 31, 2025.
Stock slips in after-hours trading
Inovio stock was trading at EUR 1.05 at Lang & Schwarz on October 2, 2026 at 9:00 p.m. CEST, down 1.87 percent versus the prior close of EUR 1.07. The primary listing is on NASDAQ in USD; the finance quote showed a market capitalization of USD 82.2 million and a 52-week range of USD 0.56 to USD 2.72 on October 2, 2026.
Inovio Pharmaceuticals market snapshot
- Company: Inovio Pharmaceuticals, Inc.
- ISIN: US45773H4092
- Ticker: INO
- Primary exchange: NASDAQ
- Price Lang & Schwarz as of October 2, 2026, 9:00 p.m. CEST: EUR 1.05
- Change versus prior close: minus 1.87 percent
- Prior close Lang & Schwarz September 30, 2026: EUR 1.07
- Market capitalization: USD 82.2 million as of October 2, 2026
- 52-week range: USD 0.56-USD 2.72 as of October 2, 2026
- Sector / Industry: Healthcare / Biotechnology
